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Detection of oxidants in uremic plasma by electron spin
resonance spectroscopy
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Detection of oxidants in uremic plasma by electron spin resonance
spectroscopy. Depletion of antioxidants and the presence of products of
free radical damage in plasma suggest that oxidative stress is increased in
uremia. We have developed an application of electron spin resonance
spectroscopy, and used this method to show that a stable oxidizing
component or components of plasma accumulate in uremia. No oxidizing
activity was detectable in plasma from subjects with normal renal function.
The oxidant was detected by its capacity to oxidize the spin trap 3,5-
dibromo-4-nitrosobenzene sulphonate (DBNBS). The oxidant was dialyz-
able from plasma, had an upper molecular weight limit of about 3,000
Daltons and was stable over many months. Physiological plasma concen-
trations of vitamin C, a water soluble congener of vitamin E and reduced
glutathione were unable to inhibit the oxidizing capacity of uremic plasma.
Thus, uremia is associated with accumulation of an endogenous oxidizing
activity at much higher concentrations than in subjects with normal renal
function.
Oxidative damage to lipids and proteins has been proposed as
an important event in the pathogenesis of atherosclerosis [1, 21,
arthritis and inflammatory diseases [3]. Atherosclerotic vascular
disease has been the leading cause of death in uremic subjects for
more than 20 years [I While hypertension and dyslipidemia are
major contributing factors to the pathogenesis of atherosclerosis,
several lines of evidence suggest there may be an increased
oxidant stress in uremic plasma contributing to the high preva-
lence of atherosclerosis associated with renal disease.
Evidence for increased oxidant stress in uremia includes low
plasma concentrations of the antioxidant vitamin C [5], although
normal concentrations have been measured [6, 7]using the same
analytical method [8]. Concentrations of vitamin E may be low in
uremic plasma [9] but normal in the low density lipoprotein
(LDL) fraction [10]. Selenium, a component of the antioxidant
enzyme glutathione peroxidase, is found in reduced concentra-
tions in uremic plasma and leukocytes [11, 12]. Concentrations of
superoxide dismutase, which catalyses the dismutation of super-
oxide radicals to hydrogen peroxide are also reduced in erythro-
cytes [13]. Concentrations of lipid peroxidation by-products are
raised in red cell membranes [14, 151 and may be further increased
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by dialysis [12, 16], providing evidence of on-going lipid peroxi-
dation in uremia. Recently, autoantibodies to oxidized LDL have
been detected in uremic plasma, suggesting enhanced LDL oxi-
dation in vivo [17].
The source of the oxidant stress in uremic subjects undergoing
dialysis has been suggested to be dialysis itself, with reactive
oxygen species being generated on the surface of dialysis mem-
branes by activation of neutrophils to produce substances detect-
able by assays of by-products of lipid peroxidation or chemilumi-
nescence [18—24]. However, endogenous oxidants peculiar to the
uremic state might also play a role.
In this study, oxidizing activity of uremic plasma was detected
by monitoring the one electron oxidation of 3,5-dibromo-4-
nitrosobenzene sulphonate (DBNBS). Oxidizing activity was
freely dialyzed, was present in patients with chronic uremia prior
to receiving any treatment, and accumulated rapidly in patients
with acute renal failure. Oxidizing activity was not inhibited by
physiological plasma concentrations of vitamin C, Trolox (a water
soluble congener of vitamin E) or glutathione, but was inhibited
by glutathione at concentrations found intracellularly. Thus, ure-
mia results in accumulation of endogenous oxidants in plasma.
Methods
Subjects
Thirteen female and 20 male subjects, age 51 13 years (mean
SD), with chronic renal failure treated by hemodialysis at the
Royal London Hospital were studied. Causes of renal failure were
(European Dialysis and Transplantation Association registry clas-
sification; number of patients): biopsy-proven chronic glomerulo-
nephritis (10; 12), non-biopsied chronic glomerulonephritis (19;
3), adult polycystic kidney disease (41; 4), insulin-dependent
diabetes mellitus (80;3), nephrolithiasis (25; 2), reflux nephropa-
thy (24; 1), acquired obstruction (23; 1), congenital obstruction
(22; 1), neurogenic bladder (21; 1), amyloidosis (83; 1), non-
insulin dependent diabetes mellitus (81; 1), unknown (0; 3).
Duration of dialysis was 3.2 3.8 years, range 0.1 to 10.9 years.
All patients were dialyzed using cuprophane membranes and
acetate or bicarbonate buffers. In addition, 13 patients with
end-stage renal disease had plasma oxidizing activity determined
prior to any treatment. Causes of renal failure in this group were:
unknown (0; 4), renal artery disease (70; 2), chronic glomerulo-
nephritis (19; 1), insulin-dependent diabetes mellitus (80; 1),
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pyelonephritis (20; 1), focal segmental glomerulonephritis (11; 1),
adult polycystic kidneys (41; 1), membranous nephropathy (14; 1),
and Henoch SchOnlein purpura (85; 1). Five laboratoiy personnel
with normal renal function provided non-uremic plasma. Samples
were also collected from patients with acute renal failure, receiv-
ing cadaveric renal allografts, or with nephrotic syndrome second-
ary to minimal change nephropathy but with a normal serum
creatinine.
Blood samples
Venous blood (5 ml) was drawn into ethylene diamine tetra-
acetic acid (EDTA) at the end of an interdialytic period, either 48
or 72 hours after the last dialysis. Plasma was separated by
centrifugation at 10°C. Creatinine and urea were determined by
autoanalyzer (Technicon, DAX). Plasma for determination of
oxidizing activity was either used immediately or stored at —70°C
until use.
For determination of the relationship between oxidizing activity
and neutrophil count, two patients on maintenance hemodialysis
were studied. Blood access was via a forearm Cimino fistula.
Blood (3.5 ml) was drawn into EDTA for determination of white
cell and neutrophil count and for determination of the oxidizing
activity. Hemodialysis was commenced, using a bicarbonate dia-
lysate and a cuprophane dialysis membrane (Organon Teknika
Nephross[TM]). Blood samples were taken from the arterial side
of the fistula (exiting the patient) at regular intervals and neutro-
phil count and oxidizing activity determined on each sample.
Samples for the measurement of oxidizing activity were stored on
ice until analysis.
To investigate the relationship between acute pathophysiolog-
ical changes in renal function and changes in oxidizing activity,
venous blood was drawn from patients undergoing renal trans-
plantation, or who were treated for acute renal failure.
Measurement of oxidizing activity
DBNBS was synthesized from 3,5-dibromosulphanilic acid (Al-
drich Chemical Company) as described by Kaur, Leung and
Perkins [251. Measurements were made using a JEOL RE1X
electron spin resonance spectrometer equiped with an X-band
microwave and integral chart recorder with a four-minute sweep
time (JEOL UK Ltd, Welwyn Garden City, Herts., UK). Spec-
trometer settings were: center field 335.0 milliTesla (mT), field
width 5 mT, field modulation width 0.32 mT, time constant 1
second, microwave power 10 mW, frequency 9.44 GHz, receiver
gain ito 10 X i0. To prevent auto-oxidation, DBNBS was stored
as the solid at 4°C and protected from light until required.
Working aliquots of 100 mivi DBNBS in phosphate buffered saline
(0.05 M NaH2PO4JNa2HPO4, pH 7.4 containing 0.15 M NaCl;
PBS), were stored in the dark at —20°C until use. The oxidizing
activity of plasma samples were determined by mixing an aliquot
of plasma and DBNBS buffered with PBS solution at zero time.
The mixture was aspirated into a quartz capillary tube, capped
and placed in the spectrometer. Oxidation of DBNBS resulted in
the appearance of a three line spectrum. Experiments were
performed to determine the change in amplitude of the three line
spectrum with time after mixing with DBNBS, plasma dilution,
DBNBS concentration, change in pH and storage of plasma
samples. Results from these preliminary studies allowed condi-
tions to be set for which the amplitude of the three line spectrum
generated by a given plasma sample was linearly related to the
oxidizing activity of that sample. This consisted of adding 190 l
PBS to 300 il plasma and 10 d DBNBS, to give a final
concentration of DBNBS of 2 m. Under these conditions, the
amplitude (signal height) of the center line of the spectrum
measured in arbitrary units and normalized to the same receiver
gain, was used as a measure of oxidizing activity.
Determination of clearance of oxidizing activity from plasma by
dialysis
Clearance of oxidizing activity was measured in 18 patients. The
dialysis circuit was modified to contain a length of sterile connect-
ing tubing of known volume, with access ports at each end in series
with the dialysis circuit between the membrane unit and the
bubble trap. Blood flow was calculated by timing the passage of an
air bubble through the tubing. The procedure was repeated three
times and the average blood flow in mis per minute determined.
Immediately after recording blood flow, samples of blood were
taken into heparin from the arterial and venous sides of the
dialysis filter. Plasma was separated and the paired samples were
either analyzed the same day (for urea and creatinine by auto-
analyzer) or stored at —40°C until determination of oxidizing
activity within 24 hours.
Preliminary characterization of oxidizing activity
To determine some of the characteristics of the oxidizing
activity in uremic plasma, oxidizing activity was measured before
and after uremic plasma was subjected to acid hydrolysis (12 M
hydrochloric acid), to trypsin or pepsin digestion (Sigma Chemi-
cals), after addition of sodium azide (100 mM; Sigma Chemicals),
or after extraction with hexane. Oxidizing activity was also mea-
sured after prolonged storage of plasma at —70°C. Because of the
pH dependence of the reaction with DBNBS, all samples were
brought to pH 7.4 for measurement of oxidizing activity.
Effect of vitamin C, glutathione and vitamin E on oxidizing
activity
Vitamin C (Sigma Chemical Co., Poole, Dorset, UK) was
prepared in a nitrogen saturated solution (50 mM) in PBS.
Ahquots were added in 190 1.d PBS to 300 pi uremic plasma to
give concentrations of 0 to 2.5 m vitamin C in a final volume of
500 jii. After five minutes, 10 p! DBNBS was added (final
concentration 2 mM), and the amplitude of the three line spec-
trum recorded after 30 minutes. Experiments were repeated four
times with aliquots of the same plasma sample.
Reduced glutathione (Sigma) was dissolved in PBS to give a 100
mM solution. Aliquots were added to 300 i.tl plasma as for vitamin
C, but giving final concentrations of 0 to 20 mivi. DBNBS was
added as above and spectral amplitude recorded at 30 minutes.
Since DBNBS is water soluble, detection of oxidizing activity by
DBNBS implies that the oxidant is water soluble. To investigate a
possible direct interaction between oxidizing activity in uremic
plasma and vitamin E, a water soluble congener of vitamin E,
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, was used
(Trolox, Sigma). The ability of Trolox to inhibit the capacity of
uremic plasma to oxidize DBNBS was performed by incubating
uremic plasma (300 jLl) with PBS (190 pA) containing Trolox to a
final concentration of 5 m and DBNBS (10 pA), final concentra-
tion 2 mM.
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Fig. 2. Measurement of oxidizing activity. The amplitude of the Center line
of the three line spectrum (h) was measured in arbitrary units and
Corrected to a receiver gain of 7.9 x i0. Thiswas termed the signal height
and was directly related to the concentration of the oxidant, determined by
dilutions of plasma samples at constant pH and temperature. The splitting
(aN) is representative of both the type of radical detected and its chemical
environment, with the unpaired electron in proximity of the nitrogen
atom.
Statistical analysis
The relationship between plasma creatinine and oxidizing ac-
tivity was determined using Spearmans rank correlation coeffi-
cient using SigmaStat for Windows (Jandel Scientific, San Rafael,
CA, USA), after testing the data for the appropriateness of using
this test. The coefficient of variation of the electron spin reso-
nance assay was 8%, determined by repeated measures (N =20).
Results
Detection of oxidizing activity
DBNBS undergoes oxidation to form a stable nitroso-cation
radical (Fig. 1). In an external magnetic field the odd electron
interacts with the nuclear spin of nitrogen, leading to a charac-
teristic three line spectrum, the amplitude of which (h, in Fig. 2)
reflects the concentration of the radical. The concentration of the
radical in turn relates to the concentration of the substances
initiating oxidation within uremic plasma.
There was a clear difference between spectra obtained from
normal and uremic plasma incubated with DBNBS. Plasma from
subjects with normal renal function produced a broad background
Fig. 3. A. Spectrum generated when plasma from an individual with normal
renal function was mixed with DBNBS (2 mM) at 20°C and pH 7.4. B.
Spectrum obtained with plasma from a patient with renal failure, taken
prior to dialysis. C. Ultrafiltrate of uremic plasma from B, molecular
weight cutoff at 3,000 Daltons. The ultrafiltration removed the broad
background signal leaving the three line signal characteristic of the
nitroso-cation radical of DBNBS.
signal and no three line spectrum (Fig. 3A). Plasma obtained from
uremic patients prior to dialysis caused DBNBS oxidation and a 3
line spectrum, characteristic of a nitroso cation radical, with
hyperfine splitting of 1.32 mT, suggesting that the DBNBS radical
was free and not covalently coupled to the oxidant (Fig. 3B). The
three line spectrum was superimposed upon a broad background
signal. DBNBS reacted with whole plasma passed through a 3,000
Dalton cut-off filter (Amicon) gave a clean three line spectrum
without the background signal (Fig. 3C). Neither plasma from
uremic or normal subjects, or DBNBS incubated alone had any
detectable spectrum.
Characterization of assay of oxidizing activity
Because the amplitude of the spectrum increased with increas-
ing pH, samples were buffered to pH 7.4 to allow comparison of
different samples (Fig. 4A). Kinetic studies showed a rise in
amplitude of the 3 line signal with time which plateaued by 30
minutes for all samples analyzed, so that comparisons of oxidizing
SO3Na
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N
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Fig. 1. Oxidation of DBNBS leads to formation of a nitroso cation radical
which is resonance stabilized by the benzene ring.
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Fig. 4. A Oxidizing activity was measured on five aliquots of the same
plasma sample from a patient with uremia, with each sample adjusted to a pH
between 6.8 and 7.6 using an appropriate phosphate buffer. Final volumes
were plasma 300 pd, phosphate buffer 190 pi, DBNBS (2 m final
concentration) 10 j.d. B. Data are shown for five individual patients. After
incubation of plasma with DBNBS and PBS at zero time, spectra were
recorded at the time intervals shown. There was a large variation in
oxidizing activity, but a plateau was reached after 30 minutes. For
comparison of oxidizing activity between plasma samples, the 30 minute
measurement was recorded. C. Plasma samples were diluted with PBS and
the 30 minute amplitude of the spectrum was recorded. Dilution led to a
linear decrease in the amplitude of the spectrum recorded, indicating that
the assay was linear for the range of oxidizing activity encountered and
conditions of the assay. Lines represent plasma samples from different
subjects.
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Fig. 5. Neutrophil count (•) and oxidizing activity (U) determined during
the first hour of hemodialysis. Each data point representing oxidizing
activity is the mean of duplicate determinations. Samples were collected as
described in Methods.
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Fig. 6. Box plot showing centiles (10th, 25th, 50th, 75th and 90th) of the
clearance of oxidizing activity, creatinine and urea in 18 patients undergoing
hemodialysis. The numbers are the means SEM.
between the amplitude of the signal and the concentration of
plasma oxidizing activity (Fig. 4C).
Relationship between peripheral blood neutrophil count and
oxidizing activity of plasma during dialysis
Figure 5 shows the relationship between whole blood neutro-
phil count and oxidizing activity in one of two patients studied
0 50 100 150 200 250 300
Plasma volume, p1
activity between samples were made at this time. Five represen-
tative samples are shown in Figure 4B. Serial dilutions of plasma
samples with a fixed concentration of DBNBS and a range of
oxidizing activities showed that there was a linear relationship
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Fig. 7. A. Association of plasma creatinine concentration with oxidizing
activity in 33 subjects on maintenance hemodialysis, prior to a hemodialysis
session (P < 0.001). Individual points are single determinations of
oxidizing activity. The c.v. of the assay was 8%. B. Oxidizing activity
determined in 13 patients with end-stage renal failure, prior to their first
hemodialysis sesssion (P = 0.11). Association was calculated using Spear-
man's rank correlation coefficient, s data points are skewed.
during the first hour of hemodialysis. The neutrophil count fell
initially, reaching a nadir at around 20 minutes, but rising again
and slightly exceeding pre-dialysis levels within the hour. The
amplitude of the ESR signal, reflecting the capacity of the plasma
sample to oxidize DBNBS, gradually decreased over the same
time period.
Clearance of oxidizing activity from plasma by dialysis
Figure 6 shows that the clearance of oxidizing activity from
plasma by dialysis was less than that of urea or creatinine. These
data are consistent with that of the filtration data reported above,
in regard to the approximate molecular mass of the oxidizing
activity.
Relationship between oxidizing activity and creatinine pre-dialysis
There was a wide variation in the oxidizing activity of plasma
from subjects on maintenance hemodialysis (Fig. 7A). However,
there was a strong association between plasma creatinine concen-
tration and oxidizing activity, determined using Spearman's rank
correlation coefficient (N = 33, P < 0.001). Oxidizing activity was
determined in 13 patients presenting with end stage renal failure,
prior to any treatment (Fig. 7B). Oxidizing activity was clearly
increased in this patient population.
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Fig. 8. A. Glutathione caused a concentration dependent decrease in oxidiz-
ing activity, but only within the intracellularly physiological range of glutathi-
one concentrations. Points are the mean of duplicate determinations with
the same plasma sample. B. Ascorbate failed to reduce oxidizing activity
within the physiological range of plasma concentrations (40 to 80 pM), hut
reduced activity at a concentration in excess of that achievable by
supplementation. Points represent the mean (N = 4). Error bars represent
the SEM.
Effect of acid hydrolysis, proteolytic digestion, azide or organic
extraction on oxidizing activity
Oxidizing activity was reduced to 10% of starting activity by acid
hydrolysis (N = 3), but was unaffected by either proteolytic
digestion with pepsin or trypsin, or treatment with the metabolic
inhibitor sodium azide. Activity was not extractable into hexane.
Storage of plasma over 72 hours at 20°C, or for over 15 months at
—70°C had no effect on the capacity of the sample to oxidize
DBNBS.
Effect of antioxidants on oxidizing activity in uremic plasma
Both glutathione and vitamin C inhibited oxidation of DBNBS
by uremic plasma. Only high concentrations of vitamin C were
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able to inhibit oxidation of DBNBS, and no effect was seen at
concentrations achievable physiologically in plasma or tissues,
even with dietary supplementation. (Fig. 8), Trolox at a concen-
tration of 5 ifiM had no effect on the ability of uremic plasma to
oxidize DBNBS. Glutathione inhibited oxidation only at concen-
trations higher than were present in plasma, although at concen-
trations that were present intracellularly.
Association of oxidizing activity with pathophysiological alter-
ations in renal function. Measurement of oxidizing activity in
patients undergoing renal transplantation, or sustaining acute
reversible renal failure, demonstrated a close pathophysiological
relationship between progressively impaired renal function and
accumulation of oxidizing activity in plasma (Fig. 9). Successful
renal transplantation was associated with rapid clearance of
oxidizing activity from plasma, followed by a slower decline in
creatinine concentration (Fig. 9A). Conversely, oxidizing activity
in plasma remained at pre-transplant concentrations with primary
non-function of the allograft (Fig. 9B). Figure 9 C and D
document the plasma creatinine and oxidizing activity profiles of
two patients who developed acute renal failure while hospitalized.
In both cases, oxidizing activity closely mirrored changes in renal
function as reflected by the plasma creatinine. Nephrotic range
proteinuria with a normal serum creatinine, occurring in three
patients with minimal change nephrotic syndrome, was not asso-
ciated with detectable oxidizing activity in plasma.
Discussion
Our results indicate that an oxidizing species, monitored by
DBNBS oxidation is present in the plasma of subjects with severe
renal disease. The oxidant apparently has a molecular weight
below 3,000 Daltons, based on the preservation of oxidizing
activity in plasma ultrafiltrates and clearance of oxidizing activity
during dialysis. Neutrophil activation was demonstrated during
dialysis by a transient fall in the peripheral neutrophil count,
confirming previous reports [19]. However, it is unlikely that
oxidizing activity was generated by neutrophil activation because
dialysis was associated with a fall in oxidizing activity. Further-
more, the presence of oxidizing activity in subjects with renal
failure prior to any treatment, the inability to detect similar
oxidizing activity in subjects with normal renal function, and the
strong positive association with plasma creatinine concentration
suggests that accumulation of oxidizing activity in plasma is a
consequence of falling glomerular filtration rate. The close rela-
tionship between oxidizing activity and changes in glomerular
filtration rate is also supported by the observations made after
transplantation and during episodes of acute renal failure.
The broad background signal generated by incubating DBNBS
with normal plasma (Fig. 3A) is indicative of some oxidation of
the DBNBS, being detected in a motionally restricted environ-
ment. Plasma or DBNBS alone generated no signal. The back-
ground signal was also present in uremic plasma but could be
filtered out using a 3,000 Dalton filter, indicating that components
of plasma causing both low levels of oxidation and motional
restriction had a molecular weight above 3,000 Daltons. The
background activity appeared of similar magnitude in all samples.
It may be indicative of an oxidant separate from that measured by
the three line spectrum, an issue that could be studied by
fractionation of plasma. In addition, oxidants would be detected
in the present system only if able to oxidize DBNBS. Therefore,
although the data demonstrate the presence of oxidizing activity
in uremic plasma, other potentially important biologically-active
oxidants could exist but be undetectable.
Previous studies of pro-oxidants in uremia have focused on
methods for determining lipid peroxidation by-products, such as
the thiobarbituric acid assay or chemiluminescence to detect
reactive oxygen species [18—24]. The thiobarbituric acid assay
measures several products of lipid peroxidation as well as other
compounds, so the results of this assay are difficult to interpret
[26]. The use of DBNBS to characterize oxidizing activity in
human plasma has not been reported. It was suggested previously
that DBNBS was oxidized by superoxide with which it formed a
stable adduct [27], but this conclusion was not substantiated by
other studies [28, 29]. Inflamed human synovial tissue was shown
to contain activity capable of oxidizing DBNBS, attributed to the
presence of superoxide radicals [30]. Later work using pulse
radiolysis showed DBNBS could act as a donor substrate to
compound I intermediates of peroxidases. Compound I interme-
diates of peroxidases are formed in the presence of hydrogen
peroxide, which is generated by dismutation of superoxide radi-
cals either spontaneously, or catalyzed by superoxide dismutase.
Thus superoxide would only be detectable indirectly, and only in
systems containing peroxidases [29]. Thus, while the assay used
here may be more specific than the thiobarbituric acic assay, it is
not possible to characterize the chemical nature of oxidizing
activity in uremic plasma from this study. It seems unlikely that
the oxidizing activity is dependent on enzymatic activity, on the
basis of its probable upper molecular mass limit, its stability and
resistance to azide, and this and previous work would suggest that
it is not due to superoxide radicals. Fractionation of ultrafiltrates
of uremic plasma by HPLC may provide further information as to
the chemical nature of the oxidant.
The presence of oxidizing activity in plasma of subjects with
impaired renal function could be interpreted as evidence of
impaired antioxidant defence mechanisms. This could occur
through interaction of oxidizing compounds with endogenous
antioxidants. Antioxidant defences in plasma include vitamin C,
which scavenges water soluble radicals and also regenerates
vitamin E, which is in turn a lipid soluble chain breaking antiox-
idant [31]. Oxidizing activity was not inhibited by physiologically
relevent concentrations of either vitamin in vitro, or by glutathi-
one. Glutathione concentrations are in the millimolar range
intracellularly, so only if the oxidant species entered cells would
there be a sufficiently high concentration of glutathione to be
protective. Thiols such as glutathione may act as antioxidants, one
mechanism being through their role as electron donors for the
enzyme glutathione peroxidase. However, they may also act as
pro-oxidants, particularly in the presence of free transition metal
ions [32, 33], when superoxide radicals, thiyl radicals and reduced
metal ions are formed. In the present system, oxidizing activity
was detected in a system containing plasma anticoagulated with
EDTA, making the presence of free transition metal ions unlikely.
This may indicate that the thiol groups on reduced glutathione are
important in inhibiting the oxidizing activity, possibly through an
enzyme independent mechanism. Within the limits of this study, it
is not possible to give further mechanistic interpretation of these
observations.
Although there is a clear relationship between alterations in
renal function and changes in oxidizing activity in a clinical
setting, direct oxidation of LDL, or cytotoxic effects related to
presence of oxidizing activity have not been demonstrated. Pro-
vision of such information will require isolation of the oxidizing
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Fig. 9. A. Fall in oxidizing activity in plasma after successful renal trans-
plantation in a 33 yr old male maintained on hemodialysis. Immunosup-
pression was attained using cyclosporine A, azathioprine and pred-
nisolone. Transplantation (day 0) was followed by a rapid decline in
oxidizing activity which paralleled the swift decline in serum creatinine. B.
Primary non-function of a renal allograft in a 36-year-old male was
associated with retention of oxidizing activity in plasma. The arrows
indicate hemodialysis sessions. C. Onset and resolution of acute oliguric
renal failure in a 48-year-old male secondary to intravascular hemolysis of
undetermined cause. Renal failure developed while the patient was
hospitalized and serial measurements showed that oxidizing activity and
serum creatinine paralleled each other. Hemodialysis was required on
days 6, 8 and 11. D. Acute non-oliguric renal failure developing after an
eclamptic seizure in a 23-year-old female. Resolution occurred without
recourse to hemodialysis. The lack of availability of blood samples prior to
the onset of renal failure did not allow the exclusion of oxidizing activity
in plasma related to the pre-eclamptic phase of her illness.
In summary, uremia is associated with accumulation of oxidiz-
ing activity in plasma, resistant to the antioxidant actions of
vitamin C, vitamin E and glutathione at physiological plasma
concentrations. It is freely dialyzable and is not the product of
dialysis. Such activity might contribute to the changes in the
oxidation status in uremic patients noted by other investigators,
and may be one factor contributing to the high prevalence of
vascular disease in the uremic population.
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components plasma. However, Maggi et al have recently shown
that susceptibility of low density lipoprotein (LDL) to copper-
induced oxidation was greater in uremic patients than controls
[10], suggesting that unidentified factors promote oxidation in
uremia. There was no difference in vitamin E content of LDL
between patients with normal renal function, and those patients
with uremia treated either conservatively, or by hemodialysis or
peritoneal dialysis. Such findings are consistent with our finding of
an endogenous oxidant in uremic plasma.
Supplementation with antioxidants to redress the accumulation
of oxidizing activity may not be appropriate, because although
resistance of LDL to in vitro oxidation has been equated with
resistance to changes that promote atherogenicity, recent evi-
dence suggests that these effects may be dissociated [34]. Further-
more, there is little consistent evidence in controlled animal
studies that antioxidants at physiological concentrations protect
against development of atherosclerosis [35].
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